Zhongke Huayi Secures Pre-A and Pre-A+ Financing to Advance Non-Invasive Brain Neuromodulation Platform

Recently, NeurPlus announced that it has successfully completed a Pre-A round and Pre-A+ round of financing worth tens of millions of RMB.ByTigerYeah Capital, Zhongke Angel, Seven Seas Capital, and Lincang Sinan FundJoint participation, the funds will be mainly used to accelerate the market expansion of approved non-invasive neuromodulation products such as transcranial electrical stimulators, develop new product pipelines, advance clinical trials, and expand the team, further enhancing NeurPlus's industry position in the field of non-invasive precise deep brain neuromodulation.

NeurPlusShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Brain Cognition and Brain Disease InstituteIncubated and established, focusing on the innovative R&D of non-invasive closed-loop neuromodulation technology, building a technology transformation platform, and providing diverse intervention, treatment, and rehabilitation solutions for brain function disorders through physical intervention methods. The product line covers various mental and neurological diseases such as cognitive impairment, Alzheimer's disease, disorders of consciousness, epilepsy, depression, and autism.

With profound scientific research accumulation and continuously expanding technical pipelines, NeurPlus has currently owned multiple independent intellectual properties in the fields of brain-computer interfaces and neuromodulation, standing out in the rapidly growing neuromodulation market.

According to a report by Future Market Insights, the global non-invasive brain stimulation market size reached US$1.2 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% to reach US$24.3 billion by 2032. In China, with the aging population and increasing societal attention on mental health, non-invasive neuromodulation technology has broad market prospects, with a patient population exceeding 100 million.The track where NeurPlus is located is rapidly expanding.

Compared with invasive neuromodulation, non-invasive neuromodulation does not involve surgery. Transcranial electrical stimulation technology is widely used in clinical applications, being relatively safe, convenient, and associated with higher patient compliance, offering new hope for treating diseases such as mild cognitive impairment, Alzheimer's disease, and depression.

As an innovative medical enterprise with cross-disciplinary integration, NeurPlus brings together multidisciplinary talents from fields such as neuroscience, psychology, materials science, and biomedical engineering to build a non-invasive closed-loop neuromodulation technology platform.Innovatively Developed "BCI+tES" Personalized Neuromodulation Solution。

Based on profound technical reserves, NeurPlusNon-invasive neural stimulation positioning, closed-loop algorithms, integrated multi-channel stimulation chips, electrode materials...and other aspects have made multiple breakthrough advancements, laying a solid foundation for comprehensive transformation from scientific research to clinical application.

With the advancement of technology, current neuromodulation techniques are showing trends towards precision, targeting, non-invasiveness, and closed-loop systems. NeurPlus, with the approach of "BCI Brain-Computer Interface + tES Transcranial Electrical Stimulation," focuses on individualized non-invasive deep brain precise closed-loop neuromodulation technology, innovatively developing proprietary technologies with full independent intellectual property rights.Closed-loop Transcranial Temporal Interference Deep Brain Stimulator。

AsGlobal Leading Non-Invasive Precision Deep Brain Closed-Loop Modulation Platform for Individualized Brain-Computer Interfaces, The closed-loop transcranial temporal interference deep brain stimulation device has overcome technical bottlenecks such as limited stimulation depth, insufficient targeting focus, and poor real-time performance associated with traditional transcranial electrical stimulation. This technological platform provides an integrated intelligent solution for scientific research and clinical applications, enabling individualized precise full-brain positioning analysis and non-invasive deep brain stimulation. It can be applied in the future toFrontier neuroscience research, as well as the treatment of various neurological or psychiatric disorders such as cognitive impairment, Alzheimer's disease, disorders of consciousness, epilepsy, depression, and attention deficit hyperactivity disorder.

NeurPlus adheres to"Individualized, Deep Brain, High Precision, Multi-Pipeline"The platform-based product development strategy is dedicated to meeting the diverse needs of clinical, research, and patient communities.

Transcranial Electrical Stimulator Granted Medical Device Registration Certificate. Based on clinical expert consensus and guidelines, this product utilizes non-invasive neuroelectrical stimulation technology. Electrodes placed on the scalp deliver low-intensity current to the cerebral cortex, modulating cortical excitability, enhancing synaptic plasticity, and influencing functional connectivity of neural networks. It delivers personalized and precise non-invasive electrical stimulation targeting the prefrontal cortex, combined with intelligent parameter configuration, offering a wide range of individualized modulation solutions for clinical use.

Transcranial Electrical Stimulator, Closed-loop Transcranial Temporal Interference Deep Electrical Stimulator, Animal Transcranial Electrical Stimulator

Source: NeurPlus

Dr. Tianrong Ji, Founding Partner of TigerYeah Capital"NeurPlus's R&D achievements in the field of non-invasive neuromodulation are remarkable. Through a closed-loop neuromodulation system and temporal interference technology, they have developed a highly precise non-invasive neuromodulation platform, applicable to various scenarios such as brain science research and clinical treatment, demonstrating strong market potential. We look forward to NeurPlus's innovative achievements benefiting a wide range of patients as soon as possible."

Dr. Guan Xinmeng, Senior Analyst of VCBeat"More than one-third of the global population is affected by neurological disorders. Based on its profound scientific research background and leading technology, NeurPlus has met the diverse clinical needs of neuromodulation, providing safe and effective innovative solutions for patients with neurological disorders, indicating a broad market prospect in the future."

LinChuang SiNanStated: "NeurPlus, relying on China's leading scientific research transformation platform and collaborating with multiple top clinical hospitals, addresses unmet clinical needs in the field of neurological diseases. By utilizing neuromodulation to treat brain function-related disorders, it will bring significant breakthroughs in medical device technology and application scenarios. The company has a rich product pipeline, including certified medical devices, and its commercialization progress is promising. This investment by VCBeat's fund in NeurPlus represents a key strategic move in the fields of neuromodulation and brain-computer interfaces, as well as an important step in serving Lingang Group's strategy to incubate cutting-edge technologies and build a brain science cluster."”

In the future, NeurPlus will continue to consolidate its technical advantages, accelerate market expansion in the field of non-invasive precise brain neuromodulation, and provide high-quality treatment solutions for patients with neurological disorders through multi-indication product portfolios and platform technology innovation. The company is committed to promoting the global application and development of non-invasive neuromodulation technologies.

TigerYeah Capital was founded in 2014 as an independent venture capital firm under Tigermed. TigerYeah Capital focuses on equity investments in early-stage and growth-stage healthcare sectors. The management team possesses deep industry background, extensive industry resources, and rich investment experience. To date, it has completed investments totaling 20 billion yuan across more than a hundred projects, with a portfolio covering medical devices, biopharmaceuticals, CROs, and health supplements. By empowering its invested companies, TigerYeah Capital creates value for the development of the healthcare industry in China and globally, contributing to public health.

CAS Angel Fund was jointly established by the CAS Technology Achievement Transformation Fund and the family capital of renowned angel investor Mr. Gong Hongjia. Adhering to the development philosophy of "pursuing the endless technological frontier, seeking business opportunities for large-scale industrialization, and supporting the growth of great enterprises," the CAS Angel Fund relies on the Chinese Academy of Sciences and is based in Shenzhen, promoting the large-scale industrialization of world-class scientific and technological achievements. The main investment areas of the CAS Angel Fund revolve around China's strategic emerging industries, primarily focusing on brain science, synthetic biology, biomedicine, artificial intelligence, new materials, and other fields. Since its operation three years ago, the fund has invested in 15 projects with a total amount of 200 million RMB, attracting over 300 million RMB in social capital post-investment, and the total valuation of its portfolio companies exceeds 3 billion RMB.

Seven Seas Capital was founded in 2014. The team members have diversified backgrounds, including senior management from well-known investment firms and technology companies, and have extensive and deep connections in innovation hubs in China (Shanghai, Shenzhen, Beijing) and the United States (Silicon Valley, New York, Boston). Seven Seas Capital focuses on investing in startups and growth-stage companies in areas such as cutting-edge artificial intelligence technology, big data, consumer, and mobile internet. It is committed to building a bridge between entrepreneurs and markets on both sides of the Pacific through investments in high-tech innovation and entrepreneurial companies in China and the United States.

The Linchuang Sinan Fund is a market-oriented science and technology innovation series fund initiated by the Lingang Group in collaboration with professional capital. It serves early-stage science and technology innovation enterprises through a technology incubation system. The Linchuang Sinan Fund focuses on cutting-edge technology fields, targeting long-term high-potential sectors, nurturing innovative companies, and building an industrial innovation ecosystem. In the life sciences sector, the Linchuang Sinan Fund concentrates on investments and incubation in high-end medical devices, early-stage innovative pharmaceuticals, and intelligent healthcare, effectively empowering startups.